


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.23%
-1.87%
+0.90%
+1.26%
HRMY
Harmony Biosciences
$29.16
Strengths

Upgraded on attractively valued

Trading below its fair value

Earnings are forecast to grow

Outperform the market
Technical Indicators

Pattern Watch

Oversold

MACD below signal line
HRMY Price Performance
$37.36 (-21.95%)
$35.34 (-17.49%)
$27.64 (+5.50%)
$34.43 (-15.31%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Has a Strong balance sheet
Above analyst estimates
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Trading below its fair value
Earnings are forecast to grow
Outperform the market
HRMY Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
HRMY Street Sentiment is extremely bullish and have positive views on the near-term outlook
HRMY has Low risk level
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Nov 25, 2025
Reiterate
Buy
HC Wainwright & Co.
Nov 25, 2025
Reiterate
Buy
Needham
Oct 23, 2025
Upgrade
Hold
Oct 16, 2025
Reiterate
Buy
UBS
Sep 25, 2025
Upgrade
Hold
What is HRMY current stock price?
What are HRMY stock strengths?
What is HRMY Risk Level?
What is HRMY market cap and volume?
What is HRMY current Stock IQ?
Should I buy HRMY stock right now?
Is HRMY a Strong Buy right now?
What does a 'Strong Buy' rating mean for HRMY?
What does a 'Strong Sell' rating mean for HRMY?
What factors influence HRMY's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
HRMY
Harmony Biosciences
Current Price
$29.16

HRMY Price Performance
$37.36 (-21.95%)
$35.34 (-17.49%)
$27.64 (+5.50%)
$34.43 (-15.31%)
HRMY Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Has a Strong balance sheet
Above analyst estimates
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Trading below its fair value
Earnings are forecast to grow
Outperform the market
HRMY Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
HRMY Street Sentiment is extremely bullish and have positive views on the near-term outlook
HRMY has Low risk level
Average key support and resistance price levels
Overall Wall Street Rating
HRMY Stock IQ
Stock Insights
Strengths

Upgraded on attractively valued

Trading below its fair value

Earnings are forecast to grow

Outperform the market
Technical Indicators

Pattern Watch

Oversold

MACD below signal line
HRMY Latest Analysis
Harmony Biosciences Holdings Becomes Oversold (HRMY). Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which me
Fri Feb 20, 2026
Earnings Preview: Harmony Biosciences Holdings Inc. (HRMY) Q4 Earnings Expected to Decline. Harmony Biosciences (HRMY) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tue Feb 17, 2026
FDA Approves Harmony Biosciences WAKIX For Pediatric Narcolepsy Patients With Cataplexy . (RTTNews) - Harmony Biosciences Holdings Inc. (HRMY) on Tuesday said that the United States Food and Drug Administration has approved its supplemental new drug application for WAKIX (pitolisant) for the treatment of cataplexy in pediatric patients aged six years and older with narcolepsy.
Tue Feb 17, 2026
Wall Street Analysts Believe Harmony Biosciences (HRMY) Could Rally 26.95%: Heres is How to Trade. The average of price targets set by Wall Street analysts indicates a potential upside of 27% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable the positive trend in earnings estimate revisions might translate into an upside in the stock.
Thu Feb 12, 2026
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?. Here at Zacks our focus is on the proven Zacks Rank system which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless we are always paying attention to the latest value growth and momentum trends to underscore strong picks.
Wed Feb 11, 2026
Zacks.com featured highlights include Harmony Biosciences Universal Health Services Concentrix and Global Payments. Harmony Biosciences stands out among value stocks as tech volatility grows with strong cash flow solid earnings surprises and growth forecasts.
Mon Feb 2, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
HRMY Stock trends
HRMY Stock performance
HRMY Stock analysis
HRMY investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.